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Abstract 
 
Heart transplantation offers the best prognostic results for patients with end stage heart failure. 
However, there is a much greater demand for donor hearts than there is adequate supply. Cold 
static storage (CSS) is the current standard protocol for donor heart procurement. CSS has 
excellent prognosis but subjects the organ to ischemic reperfusion injury (IRI) and induces tissue 
inflammation due to anoxic conditions and oxidative stress. Hearts from older donors or patients 
that have a history of previous heart disease can’t withstand the anoxic stressors and make for 
poor donor candidates with the CSS protocol since they are associated with worse prognostic 
outcomes, which restricts the donor pool for acceptable hearts. Ex vivo heart perfusion, a novel 
method for heart transport, is a potential solution to expanding the donor pool and reducing the 
IRI and anoxic insults. This protocol continuously perfuses the donor heart and has been shown 
to reduce ischemic injury, increase ex vivo viability time and improve the biochemical and 
cellular profile of the donor heart. These factors collectively open the door for the possibility of 
expanding the acceptable pool of donor hearts since this protocol places fewer stressors on the 
myocardial tissue. We review the limitations of the cold static storage protocol and evaluate the 
benefits, drawbacks and practicality of the ex vivo heart perfusion for use in clinical practice by 
examining both human and animal studies.   
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Introduction 
 
Heart transplantation has been and remains the best avenue of clinical treatment for patients with 
end stage heart failure. When pharmacological and resynchronization therapies fall short, heart 
transplants become the desired form of care to treat patients. The prognosis of transplant 
recipients is excellent, such that as of 2014 there is an 84.5% 1-year survival rate post-transplant 
and a 72.5% 5-year survival rate post-transplant.1 With the right cocktail of immunosuppressants 
and close monitoring of patient’s life and activities, 21% of patients have been documented are 
alive and healthy after 20 years post-transplant.1  
 
The issue lies with the fact that there is a significant disparity between the supply of donor hearts 
and the magnitude of qualifying recipients. To meet such high demands, alternative avenues 
have been explored including the use of total artificial hearts, ventricular assist devices and stem 
cell therapy, but they are by no means comparable to treatment via transplant.2 Thus, research 
efforts have been redirected towards expanding the possible donor pool since currently many 
potential donors are unable to donate due to the age of the organ, smoking and drug history, IV 
drug use and those with previous instances of heart disease.2 These “extended criteria hearts” 
(Table 1) are often refused because of their ability to induce primary graft failure in the recipient. 
These hearts often cause single or biventricular dysfunction and result in low cardiac output and 
hypotensive characteristics, regardless of their ability to maintain adequate atrial and ventricular 
filling pressures.3, 4 During the transplant procedure, there are repeated instances of ischemic 
stress experienced by the donor heart and it has been documented that the myocardial tissue of 
older donors are not only more susceptible to primary graft failure, but have a higher risk of 
experiencing ischemia-reperfusion injury and subsequent recovery from the injury is reduced 
relative to younger donor organs. As such, younger donor hearts are preferred for their ability to 
withstand ischemic stresses for longer periods of time without experiencing irreversible damage 
to the myocytes in the process.3, 5, 6  
 
Researchers and clinicians have looked to different means of expanding the donor pool to not 
only include these extended criteria hearts, but also to increase the time that a donor heart 
remains viable once it has been explanted. The current standard protocol of cold immersion, 
which has wonderful prognostic statistics, only has a 4-6-hour window between explantation and 
re-implantation from the donor to the recipient respectively.7 Ex vivo heart perfusion and 
donation after circulatory death (DCD) are two potential routes for expanding the donor pool that 
are being considered right now. This review will analyze recent findings on cold static storage 
and ex vivo perfusion as they relate to heart transplants.  
 
Traditional cardiac donor selection parameters 
Age < 55 years old  
No history of chest trauma or cardiac disease 
No prolonged hypotension or hypoxemia 
Appropriate hemodynamics 
     Mean arterial pressure > 60 mmHg 
     Central venous pressure 8 to 12 mmHg 
Inotropic support less than 10 mg/kg/min (dopamine or dobutamine) 
Normal electrocardiogram 
Normal echocardiogram 
Normal cardiac angiography (if indicated by donor age and history) 
Negative serology (hepatitis B surface antigen, hepatitis C virus and HIV) 
Table 1. Traditional Cardiac Donor Selection Parameters. Adapted from Sabiston & Spencer 
surgery of the chest, 8th ed. Sellke FW, del Nido PJ, Swanson SJ, et al. eds. Philadelphia: 
Saunders Elsevier, 2010). Extended criteria hearts naturally are hearts that do not fall within 
these parameters.  
 
Cold Static Storage 
 
The current gold standard for heart transplantation is via cold static storage. This method 
involves inducing cardiac arrest in the donor heart via the usage of cold crystalloid cardioplegic 
solution that serves to also flush out any leftover blood within in the heart. This is then followed 
by a cardiectomy and storage in an ice chest with the intent of placing the heart in a hypothermic 
environment to prevent metabolism. In doing so, this reduces the build of reactive oxygen 
species, accumulation of metabolic and toxic wastes and reduces ATP depletion.8 To date this 
strategy has proved both reliable and cost effective, however there are several cellular and 
systemic issues associated with this method. Despite effort to shut down metabolism, there is still 
sub physiologic levels of metabolism taking place and this results in steady depletion of ATP and 
build of ROS and toxic metabolic wastes effectively inducing acidosis in the myocardium.2, 9 
Because of these factors as well as ischemic and reperfusion stressors (during ex vivo transport 
and implantation into recipient respectively), the viability of the donor heart using this method is 
restricted to 4 – 6 hours.7, 9, 10 
 
In addition to the short viability window, hearts having undergone cold static storage experience 
ischemia-reperfusion injury (IRI) when the heart is re-introduced into the recipient as well as the 
heat-cold shock of returning to body temperature. IRI has been characterized to induce multiple 
inflammatory and cell apoptotic pathways, namely complement 3, caspase-3, caspase-8 and 
NFkB pathways.11  
 
The myocardium constitutively expresses TLR4 which activates the nuclear factor κB (NFκB) 
transcription factor. This then induces the expression of several pro-inflammatory cytokines such 
as TNF-α and IL-1β. Hypoxia resulting from the cold static storage induces expression of heat 
shock proteins (HSP60 specifically in this case) which activates TLR receptors.12 Murine models 
have shown that TLR knockout mice have reduced infarct sizes and suggest that reducing TLR 
activation during organ transplant can facilitate reduction in tissue damage.12 Since the cold 
static storage mechanism isn’t able to completely shut down metabolic processes, there is a slow 
but definite build-up of reactive oxygen species (ROS) which have also been shown activate 
TLR receptors and instigate the pathway. Effectively, the significant activation of TLR receptors 
eventually cumulates in substantial inflammatory effects in the myocardium.  
 
The activation of the pro-inflammatory cytokines (IL-6, TNF-α and IFN-γ) in turn activates the 
complement system. Complement has also been shown to be activated via the mannose binding 
lectin pathway in renal reperfusion models, suggesting that similar modes of activation in other 
tissues is also likely. Complement activation not only activates the innate immune system, 
causing inflammation, but also recruits and helps activate the adaptive immune system by 
increasing antibody secretion from B cells due to C3a and C5a.12 In a transplanted organ where 
immunosuppression is desired, complement activation and adaptive immune system recruitment 
work to hinder the host’s ability to accept the organ.  
 
By incorporating siRNAs against these molecular targets into the Celsior solution used to perfuse 
the heart has been shown to limit myocardial damage and prolong tissue preservation in cold 
storage environments in porcine models.11 Treatment with siRNAs were associated with reduced 
apoptotic markers such as BAX and reduced levels of tissue damage markers (creatine kinase, 
lactate dehydrogenase and malonaldehyde) while increasing the activity of superoxide 
dismutase.11 Effectively, treatment with siRNAs have provided insight into the inflammatory and 
apoptotic pathways that are activated in cold static storage and resultant IRI and provided a 
means to limit the damage and prolong preservation and limit tissue damage without 
compromising post-transplant organ functionality. Part of the novelty of using siRNAs is that 
they are highly specific towards their targets and are short lived. As such there are limited side 
effects, and since the effects are only short lived, the effects don’t persist for too long post-
transplant.11  
 
Treatment with siRNAs should be supplemented with activation of pro-survival signaling 
pathways. The akt pathway is one of the key pathways in regulating cardiomyocyte survival after 
ischemic stress and can be a pharmacological target to supplement siRNA treatment. 
Phosphorylation of akt and resulting downstream effects have muted the apoptotic response of 
the myocytes after being exposed to hypoxic environments.13 By manipulating this pathway, the 
infarct size and apoptotic events in cardiomyocytes have been reduced. Doxycycline use in the 
cardioplegic solution has been shown to increase the phosphorylation of the pro-survival kinase 
responsible for activating akt. As a result, doxycycline usage has facilitated reduction in the 
apoptotic events that take place after the hypoxic stressors of cold static storage and reperfusion 
injury.13 – 15  
 
Various combinations of inhibitors and activators have been experimented with to create the 
optimum drug cocktails for the ideal perfusate, however since cold static storage isolates the 
donor heart, the perfusate cocktail is limited to post-transplant or pre-transplant administration in 
a single dose, as continuous flow is not possible in the protocol. This is a major roadblock in 
increasing the viability of donor hearts and the small window for maintaining tissue integrity.  
 
Ex Vivo Continuous Perfusion 
Overview/Potential Benefits 
 
A growing field of interest is in studying the feasibility of continuous perfusion compared to cold 
storage for heart explantation and transport. Whereas cold storage arrests the heart and attempts 
to shut down metabolism, continuous perfusion seeks to do the opposite. Rather than shut down 
circulation, the heart is hooked up to a machine that circulates donor blood or synthetic perfusate 
through the myocardium. TransMedics has created one such machine to enable this process, 
referred to as the Organ Care System (OCS) which allows for both continuous perfusion of the 
heart tissue as well as consistent monitoring of the tissue’s condition.2 The OCS enables the 
transplant team to keep track of aortic pressure, coronary flow, temperature, cardiac output, heart 
rate, pressure and a lactate profile of the heart. The lactate profile of the donor heart is the best 
indicator of the patient outcome.2 OCS has been used in Australia and recently licensed for use 
in Europe as well. Clinical use in the US is still pending implementation.  
 
During cold static storage the heart is in an anaerobic environment and despite sub-physiologic 
conditions, the background levels of metabolism taking place results in energy consumption. 
These cold ischemic conditions force the heart to move from oxidative phosphorylation to lactic 
acid fermentation and concurrent build-up of lactic acid resulting in a state of acidosis.16 In 
contrast, continuous perfusion allows the circulation of fluid through the tissue to mimic the 
circulation of the body and carry away the toxic metabolites. This then effectively prevents tissue 
acidosis hence promoting tissue survival. Myocyte viability is most dependent on pH such that 
even with glucose and oxygen present, an acidic environment of pH < 6.5 has induced massive 
deaths in vitro.17 By eliminating the onset of acidic conditions, continuous perfusion is able to 
delay myocardial necrosis and increase the viability ex vivo. In addition, clinical cases have 
shown that there are over twice as many deaths post cardiac surgery in patients with pH levels 
below 6.3 and that there is approximately half the ATP present in acidic tissues compared to 
myocardium at a physiologic pH.7, 18  
 
In addition, when machine perfusion was compared to static storage, myocardial tissues samples 
have shown reduced markers of oxidative, tissue and DNA damage, reduction in oxygen and 
lactate levels (indicative that there is more aerobic and less anaerobic metabolism taking place in 
the mechanically perfused heart) and a more rapid recovery period after blood reperfusion during 
implantation of the mechanically perfused heart.9, 19 – 21  
 
As mentioned previously, the use of continuous perfusion (and demonstrated with normothermic 
perfusion) as an alternate to cold static storage drastically reduces ischemic times. This allows 
for much greater ex vivo windows and increases the retrieval boundaries for donor organs, 
allowing geography and population density to facilitate increases in the donor pool. Australia has 
had success with OCS and normothermic perfusion in that the donor heart was ex vivo for over 
10.5 hours, almost double that of a safe zone for cold static storage.2 In the context of the united 
states, donor hearts at one coast can be considered for recipients on the other and in more dire 
cases, east coast patients and western Europe can engage in organ sharing due to this increase in 
tissue viability.  
 
The increase in time available also allows for transplant and heart surgeons to gauge the quality 
of the donor heart and potentially get the donor organ typed and checked if it came from an 
emergent situation. The increase in time also gives the transplant team and the recipient patient’s 
surgeon more wiggle room in terms of coordination. With cold static storage, the recipient must 
be prepped and ready for transplant right when the donor organ arrives, to limit time spent on 
anesthesia and to not require extra time compromising the viability of the donor heart.2, 22  
 
An issue with both cold static storage and continuous perfusion is that the heart experiences 
significant edema during the process. In the case of cold static storage, the induction of ischemic 
conditions results in acidosis and toxic metabolite build-up which eventually compromises the 
cell membrane integrity and promotes fluid movement into the cell. Continuous perfusion 
doesn’t have this issue since the perfusate is usually oxygenated (allowing for aerobic 
metabolism) and washes out the metabolic waste products.9, 20 However, as soon as the heart has 
been explanted, it loses its lymphatic drainage system which then promotes tissue edema. This is 
not so problematic in the cold static treatment, but substantially more so in the continuous 
perfusion methodology since there is constant oncotic force being exerted on the tissue 
membranes. Initially constant perfusion was kept at a static pulse, which isn’t representative of 
the circulation in vivo. Mathematical models that mimic physiologic variability in circulation 
have since been integrated into the perfusion machines and this has resulted in a reduction of 
weight gain due to edema from 17% to 5% in transplanted hearts. In addition, modulation of the 
perfusate with albumin facilitates oncotic pressure regulation to further alleviate the stressors 
associated with this edema.23 – 25  
 
From a logistical and financial perspective, utilization of the Organ Care System for ex vivo 
heart perfusion and transplantation are more expensive and cumbersome relative to the standard 
cold static storage protocol. The OCS methodology necessitates a larger team and resources due 
to increased technical support staff, equipment and adequate transportation. Collection of donor 
blood is also required to prime the perfusion module of the OCS and this also requires time and 
preparation. Collectively these factors make ex vivo heart perfusion and transplantation more 
expensive than the cold static storage counterpart. However, holistically speaking, the potential 
reduction in costs due to fewer instances of recurrent surgery stemming from ischemic injury or 
primary graft failure should be considered in weighing cost benefit analyses of these two 
protocols. A paired study comparing two cases, one with cold static storage and the other with 
normothermic ex vivo perfusion (NEVP) showed that although the NEVP protocol incurred 
higher retrieval expenditures than cold static storage, but these costs were offset by the reduction 
in follow up inpatient costs. The value of better surgical outcomes and an increased donor pool 
should also be considered in evaluating the protocols’ financial burden on the healthcare 
system.2, 26  
 
Perfusate/Metabolism/Cell Mo 
 
By varying the perfusate and its additives, it is possible to increase the time spent ex vivo, 
increase the viability of the heart tissue, limit inflammation post-transplant and expand the donor 
pool even further. Celsior solution and University of Wisconsin are common perfusates used, 
especially in animal models. Between the two, Celsior has exhibited relatively higher oxygen 
consumption and glucose metabolism by the myocardium and decreased edema and reperfusion 
resistance compared to the University of Wisconsin solution. Both solutions however proved 
superior to statically preserved hearts in rat models.27 A combination of hypothermic perfusion 
and oxygenated 4 degree Celsius Celsior solution showed successful heart preservation in animal 
models at 12 and 24 hours post explantation.28  Rat and porcine models have explored the 
addition of erythropoietin (EPO), glyceryl trinitrate (a nitric oxide supplement) and zoniporide or 
cariporide (a sodium hydrogen exchange inhibitor), to hypothermic Celsior solution and reported 
dose dependent improvements in myocardial recovery after 6 hours of ischemia.29 – 31  
 
After a donor heart has been implanted, there is a natural inflammatory response in the recipient 
body as it has just undergone significant trauma. Inflammation can have adverse effects and 
harm the native and foreign tissue, however varying the pulsate formula has been shown to limit 
the host inflammatory response. Perfusate that has been fortified with mitomycin C, 
pyrazolotraizine derivatives and cariporide have been shown to reduce post-transplant 
inflammatory responses and inhibit intracellular sodium and calcium build up. Collectively these 
factors have shown to promote tissue recovery after reperfusion injury and limit the damaging 
effects of inflammation, and as a result have shown improved tissue functionality and recovery 
post-surgery.32 – 34  
 
Ex vivo perfusion has opened the floodgates with regards to the optimal perfusate and in doing 
so has also allowed for exploration of using pharmacological interventions to limit ischemic 
injuries and promote myocardial viability.2  Perfusates can also be altered to include nutritional 
supplements so that not only are old metabolic wastes washed away, but fresh nutrients and 
sources of energy can be provided to the tissue so that it can sustain aerobic metabolism.7  
Adding oxygen to the perfusate allows for aerobic metabolism to continue but also increases the 
likelihood of superoxide radical formation which can compromise the integrity of the cell 
membrane. Administration of superoxide dismutase and other enzymes that regulate free radicals 
facilitate tissue integrity. Similarly, incorporating vasodilators such as nitric oxide and sodium 
nitroprusside help establish perfusion of all the tissue. This is particularly important, since the 
harvesting process can be traumatic on the donor organ and a reduction in endothelial nitric 
oxide takes place, making it harder for homogenous tissue perfusion to take place using machine 
perfusion techniques. Incorporating vasodilators can help ameliorate that process. Other 
components of the perfusate that have been experimented with include albumin to reduce edema, 
hypocalcemic solutions to prevent intracellular accumulation, magnesium cation to maintain the 
integrity of the myocardial mitochondria and lidocaine to stabilize conduction through the tissue 
and stabilize the membrane potential.7, 9  
 
There have been some efforts to use blood as the perfusate, but issues arise with obtaining 
adequate blood volume from the donor and the efficacy of the blood under hypothermic 
conditions. Concerns with inflammatory responses and activation of coagulation factors in using 
donor blood exist and how these factors would play a role in tissue preservation and host 
rejection.7 Nonetheless, canine models have showed that reperfusion of excised heart with warm 
blood have a higher likelihood of successfully being weaned off cardiopulmonary bypass and to 
resume beating relative to cold static storage.35  
 
Hypothermic and Normothermic Perfusion 
 
Aside from considering the constitution of the perfusate in ex vivo perfusion, the optimum 
temperature of the perfusate should also be considered. Currently, hypothermic perfusate is the 
most prevalent protocol for the perfusate. It has been documented that mild hypothermia (32 – 35 
degrees Celsius) is protective against myocardial infarctions post ischemic conditions.36  
 
The rationale behind using hypothermic conditions is to protect the organs of the body from 
ischemic conditions and subsequent injury. Cooling the body and the perfusate reduces the 
metabolic rate and the oxygen consumption to free radicals and toxic metabolites form in smaller 
concentrations due to reduced flux through metabolic pathways.37 However, use of hypothermic 
conditions also can compromise the three-dimensional cellular structure and the tissue structure, 
effect enzymatic functions and reduce the ability to generate energy which can lead to apoptotic 
conditions.37  
 
Hypothermic perfusion studies have shown to be successful in the transport of extended criteria 
hearts (typically hearts that are older or come from donors with other disease). The continuous 
perfusion allows maintenance of aerobic metabolism and limits ischemic conditions which are 
less tolerated by donor hearts that are older. Continuous perfusion also helps these organs by 
providing them with a supply of metabolites which alleviates the stress of the donor heart relying 
on its own stores (which can be limited in the extended criteria organs). This effectively 
increases the donor pool not only by increasing the radius from where they can be retrieved, but 
also relaxes the criteria for a donor organ.9, 37  
 
Normothermic perfusion closely mimics physiologic conditions and thus provides an 
environment most native to the donor heart. The use of normothermic or warm blood perfusion 
has been shown to be superior to the traditional crystalloid based perfusions used to induce 
cardioplegia.38 Furthermore, studies have demonstrated that warm blood circulated through the 
donor heart tissue can be safely done, however interruption to warm perfusion can result in warm 
ischemic conditions which often results in myocardial infarctions.39, 40 For ex vivo perfusion and 
heart transplantation this is problematic when the heart is being both explanted and implanted as 
there is a natural interruption of the perfusion during these times, raising the potential for adverse 
outcomes and heart attacks.  
 
Clinical trials using normothermic solutions used for perfusion and cardioplegic solutions during 
cardiopulmonary bypass reported lower rates of infarction and higher rates of spontaneous 
defibrillation after removing the aortic cross clamping relative to the hypothermic procedures.41 
A concern for switching to normothermic solutions is the potential loss of neuroprotective 
capabilities of the hypothermic solutions. These results are inconclusive since other clinicians 
have observed in clinical trials that there was no significant difference in cognitive performance 
post-surgery between hypothermic and normothermic solutions.41   
 
A review of 6731 patients undergoing heart surgery, compared the risks and benefits of 
hypothermic and normothermic cardiopulmonary bypass. They concluded that there is no 
difference in the risk of stroke, cognitive decline, atrial fibrillation, myocardial infarction, or 
acute kidney injury between these two methods.42 They further stated that using normothermia 
during cardiopulmonary bypass is just as safe as using hypothermic conditions during cardiac 
surgery and even offer a reduced risk of experiencing allogeneic blood transfusions in 
normothermic conditions.42  
 
Stem Cells 
 
Ex vivo perfusion allows novel approaches to treating donor hearts, specifically with regards to 
mesenchymal stem cell therapy and studies have determined that use of lineage negative bone 
marrow stem cells locally delivered on infarcted cardiac tissue resulted in de novo myocardium 
formation in murine models.43 In vivo stem cell treatments are diluted, washed out and circulated 
throughout the body, preventing the stem cells to properly adhere to and occupy the target tissue. 
With ex vivo perfusion, the blood or perfusate is continually being recycled into the same organ, 
as such high dose stem cell concoctions can be delivered with greater efficacy.2 One of the goals 
of stem cell therapy in heart transplantation is to restore donor hearts that have been damaged 
due to myocardial infarctions, limit left ventricular remodeling and restore lost cardiomyocytes. 
Not only is ex vivo treatment with stem cells more feasible, but ex vivo delivery of transgenes 
and modified stem cells also attainable. Like stem cells, transgenes are at risk of being washed 
out and diluted if given in vivo or taken up by non-target cells resulting in tumors, hence it is 
preferred for a higher concentration to be administered in a smaller circuit in the ex vivo setting 
to overcome this.44 Cardiomyocytes are generally resistant to transfection protocols, however 
recent work in rat and porcine models have shown promise in delivery of the transgenes as well 
as uptake and production of the gene products of these transgenes. Specifically, vascular 
endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2). Ex vivo local 
administrations has limited the likelihood of tumor formation.45, 46  
 
Conclusion 
There is no doubt that there is a huge shortage of donor hearts compared to the long waiting list 
of recipients. Ex vivo perfusion would vastly improve this gap between the diminishing supply 
and the increasing demand. Ex vivo heart perfusion would effectively increase the retrieval 
radius for a heart, lower the restrictive criteria for acceptable hearts and with the volume of 
research being dedicated to creating the ideal perfusate, the prospect of receiving hearts with 
minimal damage and trauma is becoming increasingly feasible. Novel approaches to stem cell 
therapy and inducing protective cellular mechanisms are easier with the ex vivo perfusion 
protocol compared to the cold static storage protocol. There are numerous benefits to using this 
method for organ transport and transplant and as the protocol is further optimized, it will become 
increasingly apparent that ex vivo organ perfusion for heart transplants is the logical next step in 
improving the organ crisis for patients and health care providers.  
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